D S H Bell

Summary

Publications

  1. ncbi request reprint Diabetes: a cardiac condition manifesting as hyperglycemia
    David S H Bell
    University of Alabama School of Medicine, Birmingham, AL, USA
    Endocr Pract 14:924-32. 2008
  2. doi request reprint Combine and conquer: advantages and disadvantages of fixed-dose combination therapy
    D S H Bell
    Southside Endocrinology, University of Alabama Medical School, Birmingham, AL, USA
    Diabetes Obes Metab 15:291-300. 2013
  3. doi request reprint Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR
    David S Bell
    Clinical Professor of Medicine, University of Alabama, Birmingham, AL, USA
    Postgrad Med 124:121-35. 2012
  4. doi request reprint Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes
    D S H Bell
    Southside Endocrinology, University of Alabama Medical School, 1020 26th Street South, Birmingham, AL 35205, USA
    Diabetes Obes Metab 14:299-303. 2012
  5. ncbi request reprint Heart failure in the diabetic patient
    David S H Bell
    University of Alabama Medical School, Birmingham, AL, USA
    Cardiol Clin 25:523-38; vi. 2007
  6. doi request reprint Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome
    David S H Bell
    Southside Endocrinology, Birmingham, AL 35205, USA
    South Med J 102:413-5. 2009
  7. doi request reprint Treatment of diabetic hypertension
    David S H Bell
    University of Alabama Medical School and Southside Endocrinology, Birmingham, AL 35205, USA
    Diabetes Obes Metab 11:433-44. 2009
  8. ncbi request reprint Hypertension and diabetes: a toxic combination
    David S H Bell
    University of Alabama Medical School, Birmingham, AL 35205, USA
    Endocr Pract 14:1031-9. 2008
  9. ncbi request reprint Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?
    David S H Bell
    University of Alabama at Birmingham Medical School, Birmingham, Alabama, USA
    Drugs 67:1813-27. 2007
  10. doi request reprint Peyronie disease in association with carvedilol: a case report
    David S H Bell
    Southside Endocrinology, Birmingham, AL 35205, USA
    South Med J 101:1157-8. 2008

Detail Information

Publications74

  1. ncbi request reprint Diabetes: a cardiac condition manifesting as hyperglycemia
    David S H Bell
    University of Alabama School of Medicine, Birmingham, AL, USA
    Endocr Pract 14:924-32. 2008
    ..To investigate the reasons for the increased risk of cardiovascular events and mortality in individuals with type 2 diabetes mellitus...
  2. doi request reprint Combine and conquer: advantages and disadvantages of fixed-dose combination therapy
    D S H Bell
    Southside Endocrinology, University of Alabama Medical School, Birmingham, AL, USA
    Diabetes Obes Metab 15:291-300. 2013
    ....
  3. doi request reprint Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR
    David S Bell
    Clinical Professor of Medicine, University of Alabama, Birmingham, AL, USA
    Postgrad Med 124:121-35. 2012
    ..Therefore, bromocriptine quick release increases the range of options available to treat patients with type 2 diabetes mellitus without increasing cardiovascular risk...
  4. doi request reprint Beware the low urine pH--the major cause of the increased prevalence of nephrolithiasis in the patient with type 2 diabetes
    D S H Bell
    Southside Endocrinology, University of Alabama Medical School, 1020 26th Street South, Birmingham, AL 35205, USA
    Diabetes Obes Metab 14:299-303. 2012
    ..Prevention of nephrolithiasis can be achieved in susceptible individuals either by alkalizing the urine and/or by further decreasing the uric acid content of the urine with a xanthine oxidase inhibitor such as allopurinol...
  5. ncbi request reprint Heart failure in the diabetic patient
    David S H Bell
    University of Alabama Medical School, Birmingham, AL, USA
    Cardiol Clin 25:523-38; vi. 2007
    ..Also reviewed are the therapies that are available for the treatment of diabetic HF and whether intensifying the use of these therapies might improve the worsened clinical outcomes for the patient who has diabetes...
  6. doi request reprint Successful utilization of aliskiren, a direct renin inhibitor in Bartter syndrome
    David S H Bell
    Southside Endocrinology, Birmingham, AL 35205, USA
    South Med J 102:413-5. 2009
    ..This case report is, to my knowledge, the first to show the efficacy of a renin receptor blocker in Bartter syndrome...
  7. doi request reprint Treatment of diabetic hypertension
    David S H Bell
    University of Alabama Medical School and Southside Endocrinology, Birmingham, AL 35205, USA
    Diabetes Obes Metab 11:433-44. 2009
    ..In this review article, the benefits and disadvantages of the different antihypertensive therapies in the diabetic patient are discussed...
  8. ncbi request reprint Hypertension and diabetes: a toxic combination
    David S H Bell
    University of Alabama Medical School, Birmingham, AL 35205, USA
    Endocr Pract 14:1031-9. 2008
    ..To assess the relationship of diabetes and hypertension and the effect on cardiovascular outcomes...
  9. ncbi request reprint Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?
    David S H Bell
    University of Alabama at Birmingham Medical School, Birmingham, Alabama, USA
    Drugs 67:1813-27. 2007
    ..In addition, maximisation of glycaemic control will result in prevention, delay of onset or amelioration of both the microvascular and perhaps the macrovascular complications of diabetes...
  10. doi request reprint Peyronie disease in association with carvedilol: a case report
    David S H Bell
    Southside Endocrinology, Birmingham, AL 35205, USA
    South Med J 101:1157-8. 2008
    ..However, in this case the protective properties of carvedilol, like vasodilation and the anti-inflammatory effect, may not be sufficient to overcome its vasoconstricting beta adrenergic receptor blockade...
  11. doi request reprint Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients
    D S H Bell
    The University of Alabama, Birmingham, AL, USA
    Diabetes Obes Metab 11:234-8. 2009
    ....
  12. ncbi request reprint Triple oral therapy for type 2 diabetes
    David S H Bell
    Diabetes Res Clin Pract 78:313-5. 2007
  13. doi request reprint Resolution of statin-induced myalgias by correcting vitamin D deficiency
    David S H Bell
    Southside Endocrinology and University of Alabama Medical School, Birmingham, AL, USA
    South Med J 103:690-2. 2010
    ..This case report presents a case where cardioprotective lipid levels were achieved with a powerful statin only after correction of vitamin D deficiency...
  14. ncbi request reprint Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?
    David S H Bell
    Southside Endocrinology, Birmingham, Alabama 35205, USA
    Endocr Pract 14:112-24. 2008
    ..To investigate the association of postprandial dysmetabolism, ie, hyperglycemia, and hyperlipidemia with myocardial disease in diabetic, glucose-intolerant, and glucose-tolerant patients...
  15. ncbi request reprint Treatment of type 2 diabetes. Use of fixed-dose oral combinations
    David S H Bell
    University of Alabama at Birmingham School of Medicine, USA
    Postgrad Med 119:8-14. 2006
  16. ncbi request reprint Treatment of type 2 diabetes. The addition of injection therapy
    David S H Bell
    University of Alabama at Birmingham School of Medicine, USA
    Postgrad Med 119:15-20. 2006
  17. doi request reprint Protean manifestations of vitamin D deficiency, part 1: the epidemic of deficiency
    David S H Bell
    Southside Endocrinology, University of Alabama Medical School, Birmingham, AL, USA
    South Med J 104:331-4. 2011
    ..While vitamin D deficiency is classically associated with rickets and osteomalacia, its effects are much more protean...
  18. doi request reprint Why does quick-release bromocriptine decrease cardiac events?
    D S H Bell
    University of Alabama Birmingham, Southside Endocrinology, Birmingham, AL 35205, USA
    Diabetes Obes Metab 13:880-4. 2011
    ....
  19. doi request reprint Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II)
    D S H Bell
    Southside Endocrinology, University of Alabama Medical School, 1020 26th Street South, Birmingham, AL 35205, USA
    Diabetes Obes Metab 13:800-5. 2011
    ..Global assessments by investigators and subjects showed both a greater efficacy and tolerability with GMP...
  20. doi request reprint Metformin-induced vitamin B12 deficiency presenting as a peripheral neuropathy
    David S H Bell
    Southside Endocrinology and Division of Diabetes, Endocrinology, and Metabolism, University of Alabama Medical School, Birmingham, AL 35205, USA
    South Med J 103:265-7. 2010
    ..To my knowledge, this is the first report of metformin-induced vitamin B12 deficiency causing neuropathy...
  21. doi request reprint Therapies for diabetic dyslipidaemia
    D S H Bell
    Department of Endocrinology, University of Alabama, Birmingham, AL 35205, USA
    Diabetes Obes Metab 13:313-25. 2011
    ..Fibrates may also be of use in diabetic patients with persistently elevated triglycerides and depressed HDL-C levels, although their role in lowering adverse CV events is questionable...
  22. ncbi request reprint Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes
    D S H Bell
    The University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA
    Diabetes Obes Metab 8:110-5. 2006
    ..To describe the outcome of 35 patients with type 2 diabetes prospectively followed for 6 years after the addition of a thiazolidinedione (TZD) to a failing regimen of a sulphonylurea and metformin -- triple oral therapy...
  23. ncbi request reprint Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes
    D S H Bell
    The University of Alabama Medical School, Birmingham, AL, USA
    Diabetes Obes Metab 6:363-6. 2004
    ..Utilization of the biguanide metformin and a thiazolidinedione (TZD) with new onset diabetes has the benefit of lowering A1cs into the normal range without the problem of severe hypoglycaemia...
  24. ncbi request reprint Insulin as initial therapy for type 2 diabetes is not in the patient's best interest
    David S H Bell
    University of Alabama School of Medicine, Birmingham, Alabama 35294, USA
    Endocr Pract 10:208-12. 2004
  25. ncbi request reprint Type 2 diabetes mellitus: what is the optimal treatment regimen?
    David S H Bell
    Department of Medicine, University of Alabama at Birmingham Medical School, Birmingham, Alabama 35294, USA
    Am J Med 116:23S-29S. 2004
    ....
  26. ncbi request reprint Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus
    F Ovalle
    Department of Medicine, Division of Endocrinology and Metabolism, University of Alabama at Birmingham School of Medicine, Birmingham, AL USA
    Diabetes Obes Metab 4:56-9. 2002
    ..The aim of this study was to evaluate the effect of thiazolidinediones on the beta-cell function of patients with Type 2 diabetes mellitus (T2DM) in clinical practice...
  27. ncbi request reprint Long-term efficacy of triple oral therapy for type 2 diabetes mellitus
    David S H Bell
    Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294, USA
    Endocr Pract 8:271-5. 2002
    ..To report the status of 35 patients with type 2 diabetes mellitus approximately 3 years after the initiation of triple oral antidiabetic therapy--with a sulfonylurea, metformin, and a thiazolidinedione...
  28. ncbi request reprint A comparison of agents used to manage type 2 diabetes mellitus: need for reappraisal of traditional approaches
    David S H Bell
    School of Medicine, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA
    Treat Endocrinol 3:67-76. 2004
    ..Furthermore, early use of an insulin-sensitizing agent either alone or incombination is expected to improve both acute and long-term outcomes in patients with type 2 diabetes...
  29. ncbi request reprint Why I initiate therapy with two insulin sensitizers in patients with type 2 diabetes
    David S H Bell
    Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294, USA
    Endocr Pract 9:98-101. 2003
  30. ncbi request reprint The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis
    David S H Bell
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Alabama Medical School, Birmingham, Alabama 35294, USA
    Curr Med Res Opin 22:287-96. 2006
    ..However, some trial results indicate that carvedilol, which blocks beta1-, beta2-, and alpha1-receptors and is a potent antioxidant, may produce at least comparable effects in both patient groups...
  31. doi request reprint Rediscovering bile acid sequestrants
    D S H Bell
    Southside Endocrinology and University of Alabama Medical School Birmingham, Alabama, USA
    Diabetes Obes Metab 11:1114-21. 2009
    ..The increased risk of new-onset diabetes was in keeping with a recent meta-analysis which suggested that statins, with the possible exception of pravastatin, marginally increase the risk of developing type 2 diabetes...
  32. ncbi request reprint Advantages of a third-generation beta-blocker in patients with diabetes mellitus
    David S H Bell
    Department of Medicine, University of Alabama at Birmingham Medical School, Birmingham, Alabama 35294, USA
    Am J Cardiol 93:49B-52B. 2004
    ..However, carvedilol, a nonselective beta-blocker with vasodilating and insulin-sensitizing properties, can largely circumvent these problems and is the ideal beta-blocker for the patient with diabetes...
  33. ncbi request reprint Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes
    Fernando Ovalle
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Diabetes Care 27:2585-9. 2004
    ..To confirm our previous observations, we designed and performed a prospective, randomized, and controlled study...
  34. ncbi request reprint Lipoprotein effects of different thiazolidinediones in clinical practice
    Fernando Ovalle
    Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Alabama at Birmingham School of, Medicine, Birmingham, Alabama, USA
    Endocr Pract 8:406-10. 2002
    ..To investigate and compare the effects of troglitazone and rosiglitazone on plasma lipoproteins in patients with type 2 diabetes mellitus and dyslipidemia...
  35. ncbi request reprint Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy
    David S H Bell
    University of Alabama Medical School, Faculty Office Towers, 510 20th Street South, Room 702, Birmingham, AL 35294, USA
    Clin Ther 26:1714-27. 2004
    ....
  36. ncbi request reprint Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus
    David S H Bell
    University of Alabama at Birmingham, School of Medicine, Department of Medicine, Birmingham, USA
    Postgrad Med . 2003
    ..TZDs can be used safely in renally impaired patients with diabetes, and hepatotoxicity has not been a problem with second-generation TZDs, making these agents both safe and effective in the treatment of type 2 diabetes...
  37. ncbi request reprint Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade
    David S H Bell
    Division of Endocrinology, Department of Medicine, University of Alabama Medical School, Birmingham, AL 35294, USA
    Curr Med Res Opin 21:1191-200. 2005
    ..Despite this benefit of beta-blockers, physicians have been reluctant to use them in patients with diabetes, in whom they are even more effective, because of the negative effects on carbohydrate and lipid metabolism...
  38. ncbi request reprint Beta-cell rejuvenation with thiazolidinediones
    David S H Bell
    Division of Endocrinology, Department of Medicine, University of Alabama School of Medicine, Birmingham, Alabama 35294, USA
    Am J Med 115:20S-23S. 2003
    ..This apparent ability of TZDs to rejuvenate beta-cells, in addition to improving insulin resistance and glycemic control, is a compelling reason to use these agents as initial therapy for type 2 diabetes...
  39. ncbi request reprint The multifaceted associations of hepatobiliary disease and diabetes
    David S H Bell
    Southside Endocrinology, Birmingham, Alabama 35205, USA
    Endocr Pract 13:300-12. 2007
    ..To investigate the association of diabetes and hepatobiliary disease...
  40. pmc Advances in diabetes for the millennium: the heart and diabetes
    David S H Bell
    University of Alabama School of Medicine, Birmingham, USA
    MedGenMed 6:7. 2004
    ..Antidiabetic agents that target insulin resistance may be more cardioprotective than those that primarily augment insulin secretion...
  41. ncbi request reprint Effect of thiazolidinediones on high-density lipoprotein subfractions
    Fernando Ovalle
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, The University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
    Endocr Pract 8:102-4. 2002
    ..To evaluate the effects of thiazolidinediones (TZDs) on specific high-density lipoprotein (HDL) subfractions (HDL2 and HDL3) in patients with type 2 diabetes...
  42. ncbi request reprint Diabetic cardiomyopathy
    T Brooks Vaughan
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Heart Fail Clin 2:71-80. 2006
  43. pmc Do sulfonylurea drugs increase the risk of cardiac events?
    David S H Bell
    University of Alabama at Birmingham, Birmingham, Ala, USA
    CMAJ 174:185-6. 2006
  44. ncbi request reprint The role of C-peptide levels in screening for latent autoimmune diabetes in adults
    David S H Bell
    The University of Alabama School of Medicine, Faculty Office Tower, Room 702, 510 South 20th Street, Birmingham, AL 35294 3407, USA
    Am J Ther 11:308-11. 2004
    ..The more expensive testing for anti-GAD antibodies to definitively diagnose LADA should be reserved for patients who on screening have a low or normal random C-peptide level...
  45. ncbi request reprint 'Dead in bed syndrome--a hypothesis'
    David S H Bell
    The University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    Diabetes Obes Metab 8:261-3. 2006
  46. pmc Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus
    James H O'Keefe
    Mid America Heart and Vascular Institute and University of Missouri Kansas City, Kansas City, MO, USA
    Mayo Clin Proc 86:128-38. 2011
    ..We conducted a systematic review of English articles using MEDLINE and the Cochrane Controlled Trials Register (1970-2010) using the following search terms: cardiovascular disease, randomized trials, hypoglycemia, and insulin resistance...
  47. ncbi request reprint Hyperinsulinemic hypoglycemia precipitated by weight loss
    Maria S Prelipcean
    University of Alabama Medical School, Birmingham, AL, USA
    South Med J 98:726-8. 2005
    ..To describe a case of hyperinsulinemic hypoglycemia precipitated by weight loss...
  48. ncbi request reprint Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones
    Kathleen L Wyne
    Division of Endocrinology and Metabolism, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 8857, USA
    Postgrad Med . 2003
    ..Notably, decreasing insulin resistance also may reduce the incidence of adverse atherosclerotic consequences...
  49. ncbi request reprint Unilateral edema due to a thiazolidinedione
    David S H Bell
    Diabetes Care 26:2700. 2003
  50. ncbi request reprint Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy
    Eric S Albright
    Diabetes Care 27:632-3. 2004
  51. ncbi request reprint Thiazolidinedione-associated congestive heart failure and pulmonary edema
    David S H Bell
    Mayo Clin Proc 79:572; author reply 575-7. 2004
  52. doi request reprint Letter by Bell and O'keefe regarding article, "Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease"
    David S H Bell
    Circulation 118:e156; author reply e157. 2008
  53. ncbi request reprint Treatment of heart failure in patients with diabetes: clinical update
    David S H Bell
    Division of Endocrinology and Metabolism, The University of Alabama at Birmingham, School of Medicine, USA
    Ethn Dis 12:S1-12-8. 2002
    ..There is evidence that glycemic control is also important in improving clinical outcomes. The adverse effects of beta-blockade on carbohydrate and lipid metabolism and vasoconstriction may be circumvented by the use of carvedilol...
  54. ncbi request reprint The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial
    George L Bakris
    Rush Hypertension Center, Rush Medical Center, Suite 470, 1700 W Van Buren, Chicago, IL 60612, USA
    J Diabetes Complications 19:74-9. 2005
    ..The GEMINI trial, therefore, is the first large randomized trial to assess whether utilizing a third-generation beta-blocker yields a favorable metabolic profile in the patient with Type 2 diabetes and hypertension...
  55. ncbi request reprint Current status of diabetes treatment
    David S H Bell
    Department of Medicine, University of Alabama at Birmingham, 35294, USA
    South Med J 95:24-9. 2002
  56. ncbi request reprint Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial
    Jackson T Wright
    Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    J Clin Hypertens (Greenwich) 9:842-9. 2007
    ..The use of carvedilol compared with metoprolol did not effect glycemic control...
  57. ncbi request reprint Insulin resistance and thrombogenesis: recent insights and therapeutic implications
    Hisham A Baalbaki
    Heart Health Center PC, Florence, Alabama 35631, USA
    Endocr Pract 13:679-86. 2007
    ..To review the relationship between insulin resistance and thrombogenesis, especially in the context of obesity, diabetes, and cardiovascular disease, and to discuss therapeutic implications...
  58. ncbi request reprint Stockpiling of ovarian follicles and the response to rosiglitazone
    Tom Brooks Vaughan
    Diabetes Care 28:2333-4. 2005
  59. ncbi request reprint Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
    JAMA 292:2227-36. 2004
    ..Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers...
  60. ncbi request reprint Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor
    James H O'Keefe
    University of Missouri Kansas City, Kansas City, Missouri, USA
    Am J Cardiol 100:899-904. 2007
    ..Diet, exercise, and various pharmacologic agents can improve postprandial dysmetabolism. Using these strategies may help improve the prognosis for patients with diabetes mellitus and/or coronary heart disease...
  61. ncbi request reprint A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia: response to Goldberg et al
    David S H Bell
    Diabetes Care 28:2983-4; author reply 2985-6. 2005
  62. ncbi request reprint The decrease in microalbuminuria with carvedilol therapy is not enhanced by concurrent use of a statin
    David S H Bell
    Endocr Pract 13:808-9. 2007
  63. ncbi request reprint Heart failure: the frequent, forgotten, and often fatal complication of diabetes
    David S H Bell
    Department of Medicine, University of Alabama at Birmingham, USA
    Diabetes Care 26:2433-41. 2003
    ..Prophylactic utilization of ACE inhibitors and beta-blockers to avoid, rather than await, the need to treat HF should be considered in high-risk diabetic patients...
  64. pmc Maximally utilizing the available agents for the treatment of type 2 diabetes
    David S H Bell
    Clin Med Res 1:173-4. 2003
  65. ncbi request reprint Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes
    George L Bakris
    Rush University Medical Center, Chicago, IL 60612, USA
    Hypertension 46:1309-15. 2005
    ..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol...
  66. ncbi request reprint The effectiveness of beta-blockers after myocardial infarction in patients with type 2 diabetes
    David S H Bell
    Diabetes Care 29:483; author reply 483-4. 2006
  67. ncbi request reprint Anemia and the role of erythropoietin in diabetes
    Janet B McGill
    Washington University School of Medicine, St Louis, MO, USA
    J Diabetes Complications 20:262-72. 2006
    ..Promptly diagnosing and treating anemia in patients with diabetes may result in an improved quality of life and decreased morbidity and mortality...
  68. ncbi request reprint Diabetic cardiomyopathy
    David S H Bell
    Diabetes Care 26:2949-51. 2003
  69. ncbi request reprint Statin neuropathy masquerading as diabetic autoimmune polyneuropathy
    Tom Brooks Vaughan
    Diabetes Care 28:2082. 2005
  70. ncbi request reprint Functional class in patients with heart failure is associated with the development of diabetes
    David S H Bell
    Am J Med 115:412; author reply 412. 2003
  71. ncbi request reprint Treatment of infertility in the polycystic ovary syndrome
    David S H Bell
    N Engl J Med 356:1999-2000; author reply 2000-1. 2007
  72. ncbi request reprint C-reactive protein and glycemic control in adults with diabetes: response to King et al
    David S H Bell
    Diabetes Care 27:637; author reply 637-8. 2004
  73. ncbi request reprint Body weight changes with beta-blocker use: results from GEMINI
    Franz H Messerli
    St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
    Am J Med 120:610-5. 2007
    ....
  74. ncbi request reprint Chronic complications of diabetes
    David S H Bell
    Department of Medicine, University of Alabama at Birmingham, 35294, USA
    South Med J 95:30-4. 2002